Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 321-332

  Small, David S ^a   Li, Ying G ^a   Ernest, C Steven ^a   April, John H ^a   Farid, Nagy A ^a   Payne, Christopher D ^a   Winters, Kenneth J ^a   Rohatagi, Shashank ^b   Ni, Lan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Asian; integrated analysis; pharmacokinetics; Prasugrel; thienopyridine

Indexed keywords

DRUG METABOLITE; PRASUGREL; R 138727; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT; CAUCASIAN; FEMALE; HISPANIC; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NORMAL HUMAN; SMOKING;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOTRANSFORMATION; BODY WEIGHT; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRODRUGS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; THIOPHENES; YOUNG ADULT;

EID: 79953817883     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010367429     Document Type: Article

References (30)

1. Farid NA, Kurihara A, Wrighton SA. The metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-142.
2. 12 receptor. Curr Pharm Des. 2006;12:1255-1259.
3. 12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174-183.
4. Efient [summary of product characteristics]. http://www.emea.europa.eu/ humandocs/Humans/EPAR/efient/efient.htm. Accessed September 22, 2009.
5. Effient [package insert]. http://pi.lilly.com/us/effient.pdf. Accessed September 22, 2009.
6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
7. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite [published correction appears in J Thromb Haemost. 2007;5:1995]. J Thromb Haemost. 2007;5:1545-1551. (Pubitemid 46965386)
8. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:e9-e16.
9. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharm Ther. 2007;81:735-741. (Pubitemid 46625113)
10. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483-1494.
11. Small DS, Kothare PA, Yuen ES, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol. 2010;66:127-135.
12. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555-562. (Pubitemid 350146459)
13. Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24:2251-2257.
14. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635. (Pubitemid 44396884)
15. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
16. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
17. Li YG, Lan N, Brandt JT, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets. 2009;20:316-327.
18. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484. (Pubitemid 351389118)
19. Farid NA, Payne CD, Ernest CS II, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48:53-59. (Pubitemid 350292280)
20. Small DS, Farid NA, Li YG, et al. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. J Clin Pharm Ther. 2009;34:585-594.
21. Small DS, Wrishko RE, Ernest CS II, et al. The effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. Drugs Aging. 2009;26:781-790.
22. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:169-179. (Pubitemid 46095475)
23. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600-607.
24. Wrishko RE, Ernest CS II, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-998.
25. Braun OO, Johnell M, Varenhorst C, et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost. 2008;100:626-633.
26. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429-2436. (Pubitemid 350154353)
27. Small DS, Payne CD, Kothare PA, et al. Pharmacodynamics and pharmacokinetics of prasugrel 30-mg and clopidogrel 300-mg loading doses in healthy Chinese and Caucasian subjects. Clin Ther. 2010;32:365-379.
28. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553-2560.
29. A comparison of prasugrel and clopidogrel in Acute Coronary Syndrome subjects (TRILOGY ACS). http://clinicaltrials.gov/ct2/show/NCT00699998?term= TRILOGY+ACS&rank=1. Accessed September 22, 2009.
30. Small DS, Wrishko RE, Ernest CS II, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther. 2009;34:585-594.